CYP2A13: Key Enzyme in Drug Metabolism (G1553)

Target Name: CYP2A13

NCBI ID: G1553

CYP2A13: Key Enzyme in Drug Metabolism

CYP2A13 (CPAD) is a gene that encodes for a protein known as CYP2A13, which is a key enzyme in the metabolism of many drugs. This enzyme is involved in the conversion of drugs from their parent compounds to their active forms, which are then excreted from the body. CYP2A13 is often used as a drug target or biomarker because of its involvement in drug metabolism, and because its levels can be affected by drugs.

CYP2A13 is a member of the CYP2A family of enzymes, which are involved in the metabolism of a wide variety of drugs. The CYP2A family includes four subfamilies, including CYP2A1, CYP2A2, CYP2A3, and CYP2A4. These subfamilies are responsible for the metabolism of drugs that belong to different classes of drugs, such as benzodiazepines, opioids, and statins.

CYP2A13 is a key enzyme in the metabolism of many drugs, including many statins, benzodiazepines, and opioids. It is involved in the conversion of these drugs from their parent compounds to their active forms, which are then excreted from the body. For example, statins are drugs that are used to lower cholesterol levels, and they work by inhibiting the production of cholesterol in the liver. CYP2A13 is involved in the metabolism of these statins, converting them from their parent compounds to their active forms.

CYP2A13 is also involved in the metabolism of many other drugs, including many opioids and benzodiazepines. These drugs work by altering the levels of certain neurotransmitters in the brain, such as dopamine and GABA. CYP2A13 is involved in the metabolism of these drugs, converting them from their parent compounds to their active forms.

CYP2A13 is often used as a drug target or biomarker because of its involvement in drug metabolism. Because the levels of CYP2A13 can be affected by drugs, it can be used as a marker for the effectiveness of a drug or for the identification of potential drug interactions. For example, if a patient is taking a statin that is metabolized by CYP2A13, a drug that increases the levels of CYP2A13 may reduce the effectiveness of the statin and increase the risk of side effects.

CYP2A13 is also used as a biomarker for the detection of drug-induced liver injury (DILI). DILI is a serious complication that can occur as a result of drug use, and it is characterized by inflammation and damage to the liver. CYP2A13 is involved in the metabolism of many drugs that can cause DILI, and its levels can be affected by these drugs. Therefore, CYP2A13 can be used as a marker for the detection of DILI and for the evaluation of the effectiveness of treatments for this condition.

In conclusion, CYP2A13 is a gene that encodes for a protein involved in the metabolism of many drugs. It is often used as a drug target or biomarker because of its involvement in drug metabolism and because its levels can be affected by drugs. By studying the role of CYP2A13 in drug metabolism and drug interactions, researchers can develop better understanding of how these proteins work and how they can be targeted or used as biomarkers for a variety of diseases.

Protein Name: Cytochrome P450 Family 2 Subfamily A Member 13

Functions: Exhibits a coumarin 7-hydroxylase activity. Active in the metabolic activation of hexamethylphosphoramide, N,N-dimethylaniline, 2'-methoxyacetophenone, N-nitrosomethylphenylamine, and the tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Possesses phenacetin O-deethylation activity

More Common Targets